Previous close | 0.5010 |
Open | 0.4900 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.4900 - 0.5099 |
52-week range | 0.3650 - 1.5000 |
Volume | |
Avg. volume | 220,983 |
Market cap | 4.333M |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | 0.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
CHICAGO, August 23, 2023--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.